Tarun Kukreja, MD
Dermatology · Munster, INNPI 1760671119
Payments from drug & device makers
Across 154 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$408
- Novartis$395
- Lilly USA, LLC$249
- Sun Pharmaceutical Industries Inc.$230
- Incyte Corporation$156
- UCB, Inc.$156
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $408 |
| Novartis | 21 | $395 |
| Lilly USA, LLC | 14 | $249 |
| Sun Pharmaceutical Industries Inc. | 9 | $230 |
| Incyte Corporation | 6 | $156 |
| UCB, Inc. | 7 | $156 |
| Amgen | 6 | $147 |
| E.r. Squibb & Sons, L.L.C. | 7 | $132 |
| Kerecis Limited | 4 | $126 |
| Organogenesis Inc. | 6 | $113 |
| Sanofi | 5 | $109 |
| Johnson & Johnson | 5 | $102 |
| Regeneron Healthcare Solutions, Inc. | 3 | $93 |
| Pfizer | 5 | $77 |
| Arcutis Biotherapeutics, Inc. | 4 | $65 |
| Convatec Inc. | 2 | $57 |
| Bristol Myers Squibb | 4 | $56 |
| Mylan Pharmaceuticals Inc. | 3 | $52 |
| Boehringer Ingelheim | 2 | $50 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $50 |
| Genentech USA, Inc. | 2 | $35 |
| Dermira, Inc. | 2 | $32 |
| Fresenius Kabi USA, LLC | 1 | $27 |
| Organon | 1 | $18 |
| Mission Pharmacal Company | 1 | $17 |
| Biofrontera Inc. | 1 | $15 |
| Mimedx Group, Inc. | 1 | $15 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $14 |
| Biocon Biologics Inc | 1 | $13 |
| Merck | 1 | $12 |
How this compares
$3,020 in reported general payments places this provider in the 40th percentile of 202 dermatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 23 | $88,840 |
| Clobetasol Propionate | 76 | $2,007 |
| Fluorouracil | 30 | $1,982 |
| Ketoconazole | 58 | $1,054 |
| Doxycycline Monohydrate | 24 | $599 |
| Clindamycin Phosphate | 20 | $543 |
| Triamcinolone Acetonide | 68 | $442 |
| Imiquimod | 12 | $352 |
| Hydrocortisone | 58 | $248 |
| Cephalexin | 21 | $215 |
| Mupirocin | 28 | $140 |
| Prednisone | 14 | $79 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Munster
- Scott GuenthnerPlainfield$10.7M
- Scott FretzinIndianapolis$9.8M
- David RosmarinIndianapolis$4.4M
- Holly Hake HarrisSouth Bend$3.4M
- Megan LandisCorydon$2.8M
- Kenneth DawesIndianapolis$2.2M
- Ginat MirowskiIndianapolis$1.8M
- Vassilios DimitropoulosMichigan City$1.8M
- Christopher ObeimeIndianapolis$907K
- Megan VissingNew Albany$884K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.